Tscan Therapeutics Inc [NASDAQ: TCRX] traded at a high on Wednesday, posting a 2.80 gain after which it closed the day’ session at $4.77.
The results of the trading session contributed to over 130587 shares changing hands. Over the past one week, the price volatility of Tscan Therapeutics Inc stands at 7.49% while the volatility over the past one month is 8.15%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for TCRX stock reached $254.58 million, with 43.55 million shares outstanding and 43.47 million shares in the current float. Compared to the average trading volume of 220.01K shares, TCRX reached a trading volume of 130587 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Tscan Therapeutics Inc [TCRX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TCRX shares is $12.57 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TCRX stock is a recommendation set at 1.12. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BTIG Research have made an estimate for Tscan Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 16, 2024. While these analysts kept the previous recommendation, Needham raised their target price to Buy. The new note on the price target was released on May 13, 2024, representing the official price target for Tscan Therapeutics Inc stock. Previously, the target price had yet another raise to $8, while Wedbush analysts kept a Outperform rating on TCRX stock.
The Average True Range (ATR) for Tscan Therapeutics Inc is set at 0.34, with the Price to Sales ratio for TCRX stock in the period of the last 12 months amounting to 27.20. The Price to Book ratio for the last quarter was 1.11, with the Price to Cash per share for the same quarter was set at 5.08.
How has TCRX stock performed recently?
Tscan Therapeutics Inc [TCRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 15.78. With this latest performance, TCRX shares gained by 0.42% in over the last four-week period, additionally sinking by -42.46% over the last 6 months – not to mention a drop of -8.97% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TCRX stock in for the last two-week period is set at 48.52, with the RSI for the last a single of trading hit 52.29, and the three-weeks RSI is set at 46.89 for Tscan Therapeutics Inc [TCRX]. The present Moving Average for the last 50 days of trading for this stock 5.09, while it was recorded at 4.43 for the last single week of trading, and 6.56 for the last 200 days.
Tscan Therapeutics Inc [TCRX]: Deeper insight into the fundamentals
Tscan Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.56 and a Current Ratio set at 9.56.
Insider trade positions for Tscan Therapeutics Inc [TCRX]
There are presently around $85.74%, or 86.45%% of TCRX stock, in the hands of institutional investors. The top three institutional holders of TCRX stocks are: LYNX1 CAPITAL MANAGEMENT LP with ownership of 5.22 million shares, which is approximately 5.5068%. ECOR1 CAPITAL, LLC, holding 5.0 million shares of the stock with an approximate value of $$29.25 million in TCRX stocks shares; and ECOR1 CAPITAL, LLC, currently with $$26.1 million in TCRX stock with ownership which is approximately 4.7034%.
